• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Valeant to Acquire Leading Egyptian Pharma Firm

Article

July 17, 2015.

Valeant Pharmaceuticals has entered into an agreement to acquire Mercury (Cayman) Holdings, the holding company of Egypt's Amoun Pharmaceutical, for approximately US$800 million, plus contingent payments.

Amoun Pharmaceutical is the largest domestic company in the Egyptian pharmaceutical market with annual growth of approximately 20%. The company operates one of the largest and most up-to-date pharmaceutical facilities in Africa and the Middle East. It produces market-leading pharmaceutical brands in the anti-hypertensive, broad spectrum antibiotic and anti-diarrheal areas.    

 

Related Videos
Related Content
Stock.adobe.com

ArisGlobal Announces Second Life Sciences Generative AI Council Session

April 11th 2024
Article

The meeting is scheduled for May in Switzerland.

Image credit: ArtemisDiana | stock.adobe.com

Precision Medicine: Investments and Outcomes Expected

March 18th 2024
Article

Precision medicine is now seen as a healthcare approach for both the present and the future, particularly with the explosion of personalized care delivery.

Dan Milczarski, Executive Vice President of Process and Technology, CQfluency.

All in on AI is Not the Solution in Life Sciences and Health Care

March 13th 2024
Article

Although life science organizations are not immune to the benefits of artificial intelligence, it’s important to integrate it with caution because there is no “one-size fits all” approach.

Andrew Anderson

Normalizing Data with AI: Q&A with Andrew Anderson, VP of Innovation and Informatics Strategy at ACD/Labs

March 8th 2024
Article

Anderson discusses how AI can be used to take data collected by different processes and bring it into a usable format.

Deborah L. Ancona, Seley Distinguished Professor of Management, Professor of Organization Studies, founder of the MIT Leadership Center at the MIT Sloan School of Management.

With Generative AI, Layoffs Increasing Complexity for C-Suites in 2024, What Playbook Should Executives Deploy for the Next Three Quarters?

February 27th 2024
Article

A Harvard Business School Healthcare Alumni Association (HBSHAA) Q&A with Professor Deborah Ancona, founder of the MIT Leadership Center.

How AI is Changing the Drug Development Journey

How AI is Changing the Drug Development Journey

February 22nd 2024
Article

While no company has yet achieved the full promise of AI to radically accelerate time to market, meaningful strides are being made across the drug discovery funnel.